슬로베니아 - 슬로베니아어 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun avitum ag - glukoza, brezvodna; kalcijev klorid dihidrat; magnezijev klorid heksahidrat; natrijev hidrogenkarbonat; natrijev klorid - raztopina za hemofiltracijo - glukoza, brezvodna 9 g / 1 ml  kalcijev klorid dihidrat1,98 g / 1 ml  magnezijev klorid heksahidrat0,91 g / 1 ml  natrijev hidrogenkarbonat3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; kalcijev klorid dihidrat 1,98 g / 1 ml  magnezijev klorid heksahidrat0,91 g / 1 ml  natrijev hidrogenkarbonat3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; magnezijev klorid heksahidrat 0,91 g / 1 ml  natrijev hidrogenkarbonat3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; natrijev hidrogenkarbonat 3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; natrijev klorid 10,39 g / 1 ml - zdravila za filtracijo krvi

슬로베니아 - 슬로베니아어 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

b. braun avitum ag - glukoza, brezvodna; kalcijev klorid dihidrat; magnezijev klorid heksahidrat; natrijev hidrogenkarbonat; natrijev klorid - raztopina za hemofiltracijo - glukoza, brezvodna 9 g / 1 ml  kalcijev klorid dihidrat1,98 g / 1 ml  magnezijev klorid heksahidrat0,91 g / 1 ml  natrijev hidrogenkarbonat3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; kalcijev klorid dihidrat 1,98 g / 1 ml  magnezijev klorid heksahidrat0,91 g / 1 ml  natrijev hidrogenkarbonat3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; magnezijev klorid heksahidrat 0,91 g / 1 ml  natrijev hidrogenkarbonat3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; natrijev hidrogenkarbonat 3,59 g / 1 ml  natrijev klorid10,39 g / 1 ml; natrijev klorid 10,39 g / 1 ml - zdravila za filtracijo krvi

유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - limfom, b-celice - antineoplastična sredstva - polivy v kombinaciji z bendamustine in rituksimabom je indiciran za zdravljenje odraslih bolnikov z relapsed/ognjevzdržni razpršenih veliko b-celični limfom (dlbcl), ki niso kandidati za haematopoietic matičnih celic za presajanje. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

슬로베니아 - 슬로베니아어 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - flutikazonpropionat; salmeterol - prašek za inhaliranje, odmerjeni - flutikazonpropionat 100 µg / 1 odmerek  salmeterol50 µg / 1 odmerek; salmeterol 50 µg / 1 odmerek - salmeterol in flutikazon

슬로베니아 - 슬로베니아어 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - flutikazonpropionat; salmeterol - prašek za inhaliranje, odmerjeni - flutikazonpropionat 250 µg / 1 odmerek  salmeterol50 µg / 1 odmerek; salmeterol 50 µg / 1 odmerek - salmeterol in flutikazon

슬로베니아 - 슬로베니아어 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - flutikazonpropionat; salmeterol - prašek za inhaliranje, odmerjeni - flutikazonpropionat 500 µg / 1 odmerek  salmeterol50 µg / 1 odmerek; salmeterol 50 µg / 1 odmerek - salmeterol in flutikazon

슬로베니아 - 슬로베니아어 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

domes pharma 3 rue andré citroën 63430 pont -

유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

astrazeneca ab - olaparib - ovarijske neoplazme - antineoplastična sredstva - ciste na cancerlynparza je označen kot monotherapy za:vzdrževanje zdravljenje odraslih bolnikov z napredovalim (figo fazah iii in iv) brca1/2-mutiral (germline in/ali somatski) high-grade epitelnih jajčnikov, fallopian tube ali primarni trebušno raka, ki so v odziv (popolna ali delna) po koncu prve vrstice platinum, ki temelji kemoterapijo. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 in 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. bolniki morajo imeti predhodno že bili zdravljeni z anthracycline in taxane v (neo)adjuvant ali metastatskim nastavitev, če bolniki niso bili primerni za temi postopki (glej točko 5. bolniki z hormon receptorjev (hr)-pozitivnega raka dojk, je treba tudi napredovala na ali po predhodnem endokrine terapije, ali neprimerna za endokrine terapija. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

슬로베니아 - 슬로베니아어 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krka, d.d., novo mesto - amjodaron - tableta - amjodaron 189,3 mg / 1 tableta - amjodaron